

Ajanta House, Charkop, Kandivli West, Mumbai 400 067 India

T +91 22 6606 1000
F +91 22 6606 1200
E info@ajantapharma.com
W www.ajantapharma.com

13th January, 2016

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001

National Stock Exchange of India, Exchange Plaza, 5th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Dear Sir,

Scrip Code: BSE - AJANTPHARM 532331/ NSE - AJANTPHARM EQ

Re: Compliance with Reg. 27(2) of the Listing Regulations - Report on Corporate Governance

Pursuant to Regulation 27(2) of the Listing Regulation, enclosed please find the Quarterly Compliance Report on Corporate Governance for the quarter ended on 31st December, 2015.

Kindly acknowledge receipt.

Thanking You,

Yours faithfully, for AJANTA PHARMA LIMITED

GAURANG SHAH Sr. G.M. - Legal & Company Secretary

Encl.: a/a

Name of Listed Entity
 Quarter ending

: Ajanta Pharma Limited : 31st December, 2015

<u>₹</u> **₹** <u>₹</u> <u>₹</u> * Includes membership/chairmanship of unlisted companies also Xs. ₹ **₹** ₹ **₹** ₹. / Ms) **≩** Title Composition of Board of Directors Prabhakar Dalal Name of the Director Anjana Grewal K H Viswanathan Anil Kumar Yogesh M. Agrawal Mannalal B. Agrawal Chandrakant Madhusudan B. Purushottam B. Khetan Rajesh M. Agrawal Agrawal PAN\$ AF DIN 06896404 AFNPG6211K & 00544948 ADKPD7258G & ALJPK1873B & 00208833 AABPC8668D & 00234118 AAHPK5606M & 00302467 00073872 AACPA2742D & 06563472 AACPA2792D & 00073673 AACPA2793C & AAHPA8178J & AACPA3161C & 00073828 00073680 Executive Executive Executive Executive Chairperson Non-Independent Independent | 01.04.2014 Independent | 01.04.2014 Independent Executive/ Independent | 01.04.2014 (Chairperson Nominee) ^a independent Category /Executive/ 01.04.2014 01.04.2014 Z 01.05.2013 01.04.2013 01.04.2015 01.04.2013 Appointment Date in the current er m /cessation 앜 years years years years ₹ K ቭ lenu years X Χ X One 25(1) Directorship Listing T WO listed entities Three Regulations) Regulation (Refer including this entity listed 으 잋 Audit - 3 (*) SRC - None SRC -SRC -SRC · SRC · None SRC - None SRC - 1 Audit - None None None entity including this listed Audit/ Stakeholder Audit - 1 (*) Audit - 6 (*) Audit - 1 Audit - None Audit - 1 None memberships Number Committee(s) Listing Regulations) Regulation 26(1) of (Refer ヺ 오 entity None None Audit/ Stakeholder 잋 ð None None None None Regulation 26(1) of 8 Of 1 SRC Committee Chairperson None Committee (*) Listing Regulations) including this listed listed Committee held in 렃 post entities (Refer Audit Audit

II. Composition of Committees			
Name of Committee	Name of Committee members		Category (Chairperson/Executive/Non Executive/Independ ent/Nominee)
Audit Committee	Mr. Chandrakant Khetan Mr. Mannalal B. Agrawal	Independent I	Independent Director, Chairman of Committee
	Mr. K S Viswanathan	Independent [Independent Director, Member of Committee
	Mr. Prabhakar Dalal	Independent [Independent Director, Member of Committee
Nomination & Remuneration Committee	Dr. Anil Kumar	Independent I	Independent Director, Chairman of Committee
	Mr. Chandrakant Khetan	Independent [Independent Director, Member of Committee
	Mr. K S Viswanathan	Independent [Independent Director, Member of Committee
	Mr. Prabhakar Dalal	Independent I	Independent Director, Member of Committee
Stakeholders Relationship Committee	Dr. Anil Kumar	Independent [Independent Director, Chairman of Committee
	Mr. Rajesh M. Agrawal	Executive Dire	Executive Director, Member of Committee
	Dr. Anjana Grewal	Independent [Independent Director, Member of Committee
* Risk Management Committee is not formed as it is Not Applicable to Ajanta Pharma Limited	s Not Applicable to Ajanta Pha	arma Limited	
III. Meeting of Board of Directors			
Date(s) of Meeting (if any) in the previous quarter	ing (if	any) in the Maximum gap	Maximum gap between any two consecutive (in number of
	relevant quarter	days)	
13" August, 2015	30 th October, 2015	77 (excluding meeting days)	meeting days)
IV. Meeting of Committees			
Date(s) of meeting of the committee in the relevant quarter	it of	Date(s) of meeting of	
	Gaordin mer (oerans)	previous quarter	consecutive meetings in number of days:
Audit Committee:	Yes, all the Committee 1	13 th August, 2015	77 (excluding meeting days)
30 th October, 2015	bers were present		9 11 2 2 2 3
Stakeholders' Relationship Committee:			
	Yes, all the Committee 1	13 th August, 2015	77 (excluding meeting days)
V. Related Party Transactions			
Subject		Compliance st	Compliance status (Yes/No/NA)refer note below
Whether prior approval of audit committee obtained		Yes	
Whether shareholder approval obtained for material RPT	RPT	_	
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by	ibus approval have been review	wed by Yes	

VI. Affirmations

- 1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The composition of the following committees is in terms of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 7
 - a. Audit Committee
- Nomination & Remuneration committee
- Stakeholders relationship committee ن <u>6</u>
- The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015. 'n
 - The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
 - This report will be placed before Board of Directors at the ensuing Board meeting.

Name & Designation: Gaurang C. Shah

Company Secretary / Compliance Officer / Managing Director / CEO: Company Secretary & Compliance Officer

For AJANTA PHARMA LIMITED

GAURANG SHAH

Sr. G.M. - Legal & Company Secretary